Brokerages Set Silence Therapeutics plc (NASDAQ:SLN) Price Target at $40.67

Silence Therapeutics plc (NASDAQ:SLN) has earned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $40.67.

SLN has been the topic of a number of analyst reports. BMO Capital Markets reduced their price objective on shares of Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 4th. Morgan Stanley decreased their price target on Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, March 5th. The Goldman Sachs Group dropped their price objective on Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating on the stock in a research note on Tuesday, March 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 7th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Trexquant Investment LP bought a new stake in shares of Silence Therapeutics during the fourth quarter valued at approximately $438,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Silence Therapeutics in the 4th quarter worth $69,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Silence Therapeutics in the 4th quarter valued at $134,000. GAMMA Investing LLC increased its stake in Silence Therapeutics by 609.2% during the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after purchasing an additional 5,233 shares in the last quarter. Finally, FNY Investment Advisers LLC acquired a new position in Silence Therapeutics during the fourth quarter worth $120,000. Institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Trading Up 8.3 %

NASDAQ SLN opened at $3.14 on Friday. The firm has a market capitalization of $93.98 million, a PE ratio of -2.00 and a beta of 1.25. The business’s 50-day moving average price is $3.72 and its two-hundred day moving average price is $7.99. Silence Therapeutics has a 12 month low of $1.97 and a 12 month high of $24.38.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.